Clinical Outcomes Data
The measurement program behind MindScape Retreat's Parkinson's Disease Protocol: validated movement scales, recorded from baseline through scheduled 90-day follow-up.
The dashboard below draws its values directly from MindScape Retreat's clinical records system for the Parkinson's Disease Protocol, and it renders cohort data only once the cohort holds real assessment data. The instruments behind it span the full motor and non-motor symptom spectrum: the UPDRS (Unified Parkinson's Disease Rating Scale, the gold standard for Parkinson's motor assessment), Hoehn & Yahr staging, the Berg Balance Scale, and domain-specific scales capturing gait and balance, bradykinesia, rigidity, tremor, and bulbar function. Guests enter the program across the Hoehn & Yahr range, spanning early-to-advanced idiopathic Parkinson's disease.
This multi-scale architecture was deliberately designed to capture ibogaine's therapeutic response across distinct pathophysiological pathways: dopaminergic circuit restoration, cerebellar and brainstem motor circuit remodeling, and the neurotrophic factor upregulation that may address the underlying neurodegeneration. Tracking every scale simultaneously allows the clinical team to identify which symptom domains respond most rapidly, which require longer timelines, and whether disease stage at enrollment predicts treatment response magnitude.
What guests and caregivers describe, and what the clinical team watches for in the trajectory data, is a differential response across motor domains that carries meaningful mechanistic implications. Gait and balance, along with bulbar function (speech clarity, swallowing efficiency, and sialorrhea control), are frequently the domains where change is noticed earliest. That pattern would suggest ibogaine's neurotrophic factor upregulation preferentially engages the brainstem and cerebellar circuits affected in early-to-moderate Parkinson's disease. These circuits rely heavily on GDNF-responsive dopaminergic and non-dopaminergic pathways that appear particularly sensitive to ibogaine's neuroprotective effects. Whether the pattern holds at the cohort level is precisely what the measurement program exists to establish.
Tremor is the domain in which guests most often describe a more modest response, consistent with tremor-predominant Parkinson's disease's distinct pathophysiology. Tremor circuits in Parkinson's involve thalamic oscillatory networks (specifically the ventral intermediate nucleus) that operate through pathways partially distinct from the nigrostriatal dopaminergic system driving rigidity and bradykinesia. This differential response profile is not a limitation but rather a diagnostic signal: it suggests that ibogaine's mechanism may engage dopaminergic and brainstem circuits with greater specificity than the thalamic circuitry underlying tremor, which may benefit from complementary interventions in tremor-predominant presentations.
Study Overview
An Exploratory Program. 14 to 18 Day Protocol. Every Guest Measured.
MindScape Retreat in Cozumel, Mexico runs an exploratory clinical program for people diagnosed with Parkinson's disease across the Hoehn & Yahr range. Guests undergo a comprehensive 14 to 18 day ibogaine therapy program under daily physician supervision with neurological monitoring throughout, and every guest is assessed on a battery of validated movement scales rather than on impressions.
We publish no efficacy percentages for this program, because there are none that could be published honestly yet. The MDS-UPDRS motor examination is the primary endpoint, supported by Hoehn & Yahr staging, the Berg Balance Scale, and domain-specific gait, bradykinesia, rigidity, tremor, and bulbar scales. Scores are recorded on a fixed schedule from baseline through Day 90 follow-up, and cohort aggregates publish at mindscaperetreat.com/outcomes once at least 20 people have paired data.
The program is built on preclinical evidence demonstrating ibogaine's capacity to upregulate GDNF, a key neuroprotective factor for dopaminergic neurons, and on the recognition that this mechanism has never been systematically measured in human Parkinson's care. Measuring it properly is the point.
UPDRS Part III, the Motor Examination, is the universally accepted primary endpoint for Parkinson's therapeutic efficacy trials and the standard by which all interventions, from levodopa to deep brain stimulation, are benchmarked. This 33-item clinician-administered assessment evaluates speech, facial expression, rest tremor across all body segments, action and postural tremor, rigidity at neck and limbs, finger tapping, hand movements, rapid alternating hand movements, leg agility, arising from a chair, posture, gait, postural stability, and global body bradykinesia. The comprehensiveness of UPDRS Part III is what makes it the definitive motor outcome measure: it captures the full clinical expression of Parkinson's motor impairment in a single standardized score.
The direction of change matters as much as the magnitude in any single domain. Bulbar improvement translates directly into the speech intelligibility and reduced drooling that family members and caregivers notice immediately and that profoundly affect quality of life. Gait and balance speak to fall risk, one of the most consequential complications of advancing Parkinson's disease, which is why the Berg Balance Scale is recorded alongside the motor examination rather than inferred from it.
Some guests and their neurologists have observed reduced levodopa requirements after treatment. We treat that as a hypothesis to be tested rather than a result to advertise, because it is exactly the kind of observation that selection and expectation can manufacture in an uncontrolled setting. It is consistent with ibogaine's proposed GDNF-mediated neuroprotective mechanism, which would predict partial restoration of endogenous dopaminergic capacity rather than simple receptor modulation layered on top of progressive degeneration, and it is one of the outcomes the measurement schedule is built to capture.
How the Program Is Designed and Measured
Study Design
Prospective, single-center observational design with 90-day longitudinal follow-up. Guests are enrolled across the Hoehn & Yahr range, and analysis is stratified by disease stage at enrollment (early, moderate, and advanced) so that response can be read against baseline severity rather than averaged over it. Every assessment is recorded in the clinical records system. Written informed consent.
Inclusion Criteria
Adults aged 40 to 80 with confirmed idiopathic Parkinson's disease diagnosis (UK Brain Bank criteria). H&Y stage 1 to 4. Stable dopaminergic medication regimen for ≥ 3 months. Cardiac clearance (QTc < 450ms). Exclusion: atypical parkinsonism, H&Y stage 5, severe cognitive impairment (MMSE < 20), deep brain stimulation, or significant cardiac arrhythmia.
Assessment Instruments
Primary: Unified Parkinson's Disease Rating Scale (UPDRS, Motor Section III). Secondary: Hoehn & Yahr staging (1 to 5), Berg Balance Scale (0 to 56, higher = better). Domain-specific scales: PD Gait & Balance (0 to 40), PD Bradykinesia (0 to 20), PD Rigidity (0 to 20), PD Tremor (0 to 28), PD Bulbar/Voice (0 to 20). All assessments conducted by movement disorder-trained clinician.
Assessment Schedule
Standardized timepoints: Baseline (pre-treatment), Day 3 post-ibogaine, Day 7, Day 14 (discharge), Day 30, Day 60, and Day 90 follow-up. Motor assessments conducted in 'off' state (≥ 12h after last dopaminergic dose) at baseline and Day 90 for controlled comparison. All interim assessments in 'on' state.
Neuroprotection Hypothesis
The program is designed to assess ibogaine's potential GDNF-mediated neuroprotective effects in Parkinson's disease based on preclinical evidence (He et al., 2005) demonstrating ibogaine-induced GDNF upregulation in dopaminergic neurons. The 14 to 18 day treatment protocol exceeds standard ibogaine addiction treatment duration to maximize the neuroplasticity window for neurodegenerative benefit. It is exploratory by design, which is exactly why it is measured this closely.
Safety Monitoring
Continuous cardiac telemetry during treatment. Dopaminergic medication management: patients maintained on baseline L-DOPA/carbidopa with physician-supervised dose adjustments during the treatment period. Fall risk protocol with daily Berg Balance Scale assessment during inpatient phase. Neurological adverse events documented by attending neurologist.
Mechanism of Action
GDNF Upregulation: Addressing Neurodegeneration at the Source
Ibogaine promotes the release of glial cell line-derived neurotrophic factor (GDNF), a protein that protects and supports the survival of dopaminergic neurons. GDNF is among the most studied neuroprotective agents in Parkinson's research, and its upregulation represents a fundamentally different therapeutic target than symptomatic L-DOPA replacement.
Parkinson's is characterized by progressive degeneration of dopaminergic neurons in the substantia nigra. Preclinical data suggest ibogaine may support regeneration through GDNF-mediated neuroprotection, addressing the underlying neurodegeneration rather than merely compensating for dopamine deficiency.
Beyond dopaminergic pathways, ibogaine promotes broader neuroplasticity through BDNF and serotonergic modulation. Its sigma-1 receptor agonism and modulation of glial cell activity may also reduce neuroinflammatory cascades, slowing disease progression beyond what symptomatic medications achieve.
What We Measure, and What Guests Describe
There are no published human efficacy trials of ibogaine for Parkinson's disease. That is the honest starting point, and it is why this program measures rather than markets. The MDS-UPDRS motor examination is the primary endpoint, supported by a battery of validated movement scales, and no outcome figure appears on this page until a real cohort supports one.
The mechanistic case is strong and it does not depend on us. GDNF is among the most studied neuroprotective pathways in Parkinson's research, preclinical work demonstrates ibogaine-induced GDNF upregulation in dopaminergic neurons (He et al., 2005), and human trials of surgically infused GDNF have shown clinical benefit. Ibogaine and noribogaine cross the blood-brain barrier without neurosurgery, which is what makes this pathway worth measuring in the first place.
Many guests and caregivers describe meaningful improvement in daily motor function in the weeks following treatment: steadier walking, easier turning, less rigidity on waking, more reliable fine motor control. These are qualitative reports, recorded and presented as such, and they are the reason the formal scales matter.
Gait, balance, and bulbar function are the domains in which caregivers most often notice change first. Berg Balance Scale scores are recorded alongside the motor examination because fall risk is a concrete, consequential endpoint rather than a subjective impression.
Disease stage at enrollment is tracked on Hoehn & Yahr staging and the analysis is stratified by it, because the neuroprotection hypothesis predicts that benefit is greatest when treatment begins before extensive neurodegeneration. That prediction is testable, and stratified measurement is how it gets tested.
Across more than 1,000 guests treated since 2019, zero serious complications have been recorded. In the Parkinson's program specifically, no falls or serious neurological adverse events occurred during treatment or the recovery period. Cohort outcome aggregates publish at mindscaperetreat.com/outcomes once at least 20 people have paired data, and never before.
Treatment Protocol
14 to 18 Day Neurological Ibogaine Protocol
Neurological Assessment
Comprehensive evaluation of Parkinson's stage, current L-DOPA regimen, motor and non-motor symptoms, and disease progression timeline. We establish baseline UPDRS scores to measure treatment outcomes objectively. A detailed medication reconciliation is performed to assess all interactions.
Medical Screening & Cardiac Clearance
Full bloodwork, EKG, and cardiovascular evaluation. Parkinson's patients undergo additional assessment given the complexity of existing medication regimens and cardiovascular considerations unique to neurodegenerative conditions. Contraindications are assessed rigorously before acceptance.
Custom Protocol Design
Our medical director designs a personalized ibogaine protocol accounting for disease stage, current medications, and specific symptom profile. Parkinson's protocols differ significantly from addiction protocols in both dosing and supportive care, requiring more conservative initial dosing with progressive escalation.
14 to 18 Day Treatment in Cozumel
Extended treatment program with continuous physician and nursing oversight. Neurological monitoring is maintained throughout. The 14 to 18 day protocol allows for progressive dosing and real-time assessment of motor function improvements, with protocol adjustments made based on daily clinical observations and disease stage.
Integration & 90-Day Follow-Up
Structured 90-day follow-up framework with neurological reassessment at 30, 60, and 90 days. Patients are monitored for sustained GDNF-mediated neurological improvements and for any changes to their existing medication requirements following treatment.
Frequently Asked Questions
Questions About Ibogaine for Parkinson's Disease
Supporting Literature & Citations
Every MindScape treatment program includes a guided 5-MeO-DMT (Bufo) ceremony, part of the all-inclusive price, not an add-on.
Start a Confidential Conversation
100% Confidential · No Obligation · Response Within 24 Hours
Get our Medical Credentials & Patient Safety Packet
15 pages: our physicians and licenses, cardiac safety standards, emergency protocols, travel guidance, and answers to the questions families ask most.
No spam, ever. Or download it directly without sharing your email.
100% Confidential · No Obligation · Available 7 Days a Week